文献速递甲状腺疾病

RAS突变甲状腺结节分子决定因素:细胞学不确定结节的基因表达与血管生成素-2研究

Molecular Determinants of Thyroid Nodules with Indeterminate Cytology and RAS Mutations.
PubMed 文献 · Thyroid · 2020-08-25

研究对61个RAS突变甲状腺结节按组织学诊断和生物学行为分为五类(非肿瘤性、良性肿瘤、恶性潜能未定、低危癌、高危癌),用NanoString PanCancer Pathways和IO 360 Panel分析差异表达基因,并用免疫组化检测血管生成素-2。结果发现细胞周期与凋亡、PI3K通路及间质因子相关基因表达与恶性程度显著相关,血管生成素-2免疫组化表达从非肿瘤性到高危癌呈递增趋势(p < 0.0001)。作者认为RAS突变结节存在阶梯式进展,ANGPT2表达作为潜在诊断标志物值得进一步评估。

要点

  • 61个RAS突变甲状腺结节按组织学与生物学行为分为五类,覆盖非肿瘤性至高危癌。
  • 细胞周期与凋亡、PI3K通路及间质因子相关基因表达与恶性程度显著相关。
  • 血管生成素-2免疫组化表达从非肿瘤性到高危癌递增(p < 0.0001)。

核心结论

  • RAS突变甲状腺结节的基因表达分析提示关键致癌通路随恶性程度增加而上调,支持阶梯式进展的概念。
  • ANGPT2表达作为潜在诊断标志物的效用值得进一步评估。

研究设计与样本

  • 共识别61个RAS突变甲状腺结节,按组织学诊断和生物学行为分为五类:非肿瘤性、良性肿瘤、恶性潜能未定、低危癌、高危癌。
  • 使用NanoString PanCancer Pathways和IO 360 Panels测定基因表达谱,并用免疫组化检测血管生成素-2水平。

主要发现

  • 以五类为监督参数分析差异表达基因,发现恶性程度与细胞周期和凋亡相关基因(BAX、CCNE2、CDKN2A、CDKN2B、CHEK1、E2F1、GSK3B、NFKB1、PRKAR2A)显著相关。
  • 恶性程度与PI3K通路相关基因(CCNE2、CSF3、GSKB3、NFKB1、PPP2R2C、SGK2)显著相关。
  • 恶性程度与间质因子(ANGPT2、DLL4)显著相关。
  • 免疫组化显示血管生成素-2表达从非肿瘤性到高危癌呈相同递增趋势(p < 0.0001)。

关键数值与推荐

  • 血管生成素-2免疫组化表达从非肿瘤性外观到高危癌递增,p < 0.0001。

临床怎么用

  • 作者认为ANGPT2表达作为潜在诊断标志物的效用值得进一步评估。

局限性

  • 原文指出ANGPT2表达作为潜在诊断标志物的效用值得进一步评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background:RAS gene family mutations are the most prevalent in thyroid nodules with indeterminate cytology and are present in a wide spectrum of histological diagnoses. We evaluated differentially expressed genes and signaling pathways across the histological/clinical spectrum of RAS-mutant nodules to determine key molecular determinants associated with a high risk of malignancy. Methods: Sixty-one thyroid nodules with RAS mutations were identified. Based on the histological diagnosis and biological behavior, the nodules were grouped into five categories indicating their degree of malignancy: non-neoplastic appearance, benign neoplasm, indeterminate malignant potential, low-risk cancer, or high-risk cancer. Gene expression profiles of these nodules were determined using the NanoString PanCancer Pathways and IO 360 Panels, and Angiopoietin-2 level was determined by immunohistochemical staining. Results: The analysis of differentially expressed genes using the five categories as supervising parameters unearthed a significant correlation between the degree of malignancy and genes involved in cell cycle and apoptosis (BAX, CCNE2, CDKN2A, CDKN2B, CHEK1, E2F1, GSK3B, NFKB1, and PRKAR2A), PI3K pathway (CCNE2, CSF3, GSKB3, NFKB1, PPP2R2C, and SGK2), and stromal factors (ANGPT2 and DLL4). The expression of Angiopoietin-2 by immunohistochemistry also showed the same trend of increasing expression from non-neoplastic appearance to high-risk cancer (p < 0.0001). Conclusions: The gene expression analysis of RAS-mutant thyroid nodules suggests increasing upregulation of key oncogenic pathways depending on their degree of malignancy and supports the concept of a stepwise progression. The utility of ANGPT2 expression as a potential diagnostic biomarker warrants further evaluation.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Hernandez-Prera JC, Valderrabano P, Creed JH, et al. Molecular Determinants of Thyroid Nodules with Indeterminate Cytology and RAS Mutations. Thyroid. 2020. PMID: 32689909. doi:10.1089/thy.2019.0650

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。